We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $3.5B
1-Year Est. Return 1,165.83%
This Fund
S&P 500
This Quarter Est. Return
-11.22%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$960M
AUM Growth
-$305M
Cap. Flow
-$75.3M
Cap. Flow %
-7.85%
Top 10 Hldgs %
64.7%
Holding
35
New
2
Increased
6
Reduced
4
Closed
3

Top Buys

1
ABVX
Abivax
ABVX
+$70.9M
2
IRON icon
Disc Medicine
IRON
+$16.5M
3
EYPT icon
EyePoint Inc
EYPT
+$12.9M
4
SVRA icon
Savara
SVRA
+$10.5M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$8.06M

Top Sells

1
INBX
Inhibrx, Inc. Common Stock
INBX
+$61.2M
2
GERN icon
Geron
GERN
+$57.4M
3
GPCR icon
Structure Therapeutics
GPCR
+$37.1M
4
ATXS
Astria Therapeutics
ATXS
+$24.6M
5
KALV
KalVista Pharmaceuticals
KALV
+$13.8M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCCC icon
26
C4 Therapeutics
CCCC
$408M
$5.9M 0.61%
1,276,574
– –
NKTR icon
27
Nektar Therapeutics
NKTR
$2.31B
$4.96M 0.52%
266,667
– –
JBIO
28
Jade Biosciences
JBIO
$1.27B
$3.72M 0.39%
64,023
+1,129
+2% +$749K
ANTX icon
29
AN2 Therapeutics
ANTX
$169M
$3.34M 0.35%
1,555,118
– –
KOD icon
30
Kodiak Sciences
KOD
$2.67B
$2.11M 0.22%
899,999
– –
VTYX
31
DELISTED
Ventyx Biosciences
VTYX
$730K 0.08%
316,195
-499,529
-61% -$2.08M
CABA icon
32
Cabaletta Bio
CABA
$461M
$649K 0.07%
86,795
– –
GERN icon
33
Geron
GERN
$924M
– –
-17,391,639
Closed -$57.4M
KALV
34
DELISTED
KalVista Pharmaceuticals
KALV
– –
-1,163,356
Closed -$13.8M
INBX
35
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-1,750,387
Closed -$61.2M
1
2

Similar funds

DILIC
Dai-ichi Life Insurance Company Tokyo, Japan $3.49B AUM 27.28% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.51B AUM 39.24% 1-Year Est. Return
KCM
Kedalion Capital Management London, United Kingdom $3.48B AUM 17.74% 1-Year Est. Return
ACM
Aquatic Capital Management Chicago, Illinois $3.48B AUM 24.9% 1-Year Est. Return
BCP
BDT Capital Partners Chicago, Illinois $3.51B AUM 31.02% 1-Year Est. Return
AL
Aspiriant LLC Los Angeles, California $3.51B AUM 13.98% 1-Year Est. Return
ACA
Anchor Capital Advisors Boston, Massachusetts $3.51B AUM 16.99% 1-Year Est. Return
MSC
MUFG Securities (Canada) New York $3.48B AUM 45.13% 1-Year Est. Return

TCG Crossover Management's Q2 2024 Portfolio in Review

As of Q2 2024, TCG Crossover Management held 35 positions worth $960M, down 24% from $1.26B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

TCG Crossover Management withdrew a net $75.3M in Q2 2024, closing 3 positions and reducing 4 holdings. Its most notable exit was Inhibrx, Inc. Common Stock, an estimated $61.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, TCG Crossover Management opened a new position in Disc Medicine worth $21.9M.

  • TCG Crossover Management's largest Q2 2024 buy was Disc Medicine: 486,957 shares worth $21.9M.
  • TCG Crossover Management added most to Abivax in Q2 2024, an estimated $70.9M increase.
  • TCG Crossover Management's biggest Q2 2024 reduction was Structure Therapeutics, cutting an estimated $37.1M.
  • TCG Crossover Management fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $61.2M.
  • TCG Crossover Management's ten largest holdings make up 65% of its $960M portfolio in Q2 2024.
  • TCG Crossover Management opened 2 new positions and closed 3 in Q2 2024.
  • TCG Crossover Management's portfolio value fell 24% quarter-over-quarter to $960M.

Based on TCG Crossover Management's 13F filing for Q2 2024, filed 14 Aug 2024.